Imagen de Portada

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Carolyn Singleton, Allie Carter, Brittany Baker, Emma Jones, Kelsey Green, Craig Lammert, Lauren D. Nephew
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
por: Julian Hercun, et al.
Publicado: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
por: Lukas Hartl, et al.
Publicado: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
por: Philip Vutien, et al.
Publicado: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
por: Jung Eun Park, et al.
Publicado: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2024)

Review article: Current status and future directions of ingestible electronic devices in gastroenterology
por: Phoebe A. Thwaites, et al.
Publicado: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
por: Jianrong Li, et al.
Publicado: (2024)

Editorial: Can dietary gluten restriction improve hepatic steatosis?
por: Hariklia Kranidioti, et al.
Publicado: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
por: Na‐Ling Kang, et al.
Publicado: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
por: Chen‐Pi Li, et al.
Publicado: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
por: Jian Wang, et al.
Publicado: (2024)

Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C
por: Nikolaos Papadopoulos, et al.
Publicado: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
por: Matthew J. Townsend, et al.
Publicado: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
por: Vishnu Girish, et al.
Publicado: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
por: Hyeyeon Hong, et al.
Publicado: (2024)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
por: Elena Vargas‐Accarino, et al.
Publicado: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
por: Nabil Noureddin, et al.
Publicado: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
por: Jian Wang, et al.
Publicado: (2024)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
por: Ann T. Ma, et al.
Publicado: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
por: Jing Li, et al.
Publicado: (2024)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
por: Lauren Holtslander, et al.
Publicado: (2025)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
por: Hye Won Lee, et al.
Publicado: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
por: Lisa Sandmann, et al.
Publicado: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
por: WenXian OuYang, et al.
Publicado: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
por: Akshatha Kiran, et al.
Publicado: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
por: Eiichi Ogawa
Publicado: (2024)

Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
por: Irene Ligato, et al.
Publicado: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
por: Haibo Jing, et al.
Publicado: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis
por: Yusuf Yilmaz
Publicado: (2024)

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints
por: Philippe Sultanik, et al.
Publicado: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
por: Jian Wang, et al.
Publicado: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
por: Maria Buti, et al.
Publicado: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
por: Yen‐Chun Liu, et al.
Publicado: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
por: Andrea Martini, et al.
Publicado: (2024)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2025)

Review article: Evidence‐based dietary management of inflammatory bowel disease
por: Peter R. Gibson, et al.
Publicado: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
por: Rui Zhang, et al.
Publicado: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
por: Basile Njei, et al.
Publicado: (2024)